Clinical Trials Logo

Clinical Trial Summary

The investigators intend to utilize reduced intensity conditioning and allogeneic stem cell transplant from EBV positive HLA matched sibling or unrelated adult donor combined with post AlloSCT allogeneic donor derived LMP specific cytotoxic T-lymphocyte (CTL) infusions in EBV positive patients with poor risk Hodgkin Lymphoma. One of three reduced intensity conditioning regimens predetermined at each institutional center of the Childhood, Adolescent and Young Adult Lymphoma Cell Therapy Consortium (LCTC) will be utilized for related or matched unrelated adult donor allogeneic transplant followed by donor LMP specific CTL infusion for three doses post AlloSCT. The investigators hypothesize that the addition of donor derived LMP specific CTLs will be safe and feasible.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01636388
Study type Interventional
Source New York Medical College
Contact
Status Terminated
Phase Phase 2
Start date January 2013
Completion date December 2017

See also
  Status Clinical Trial Phase
Terminated NCT00383097 - Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma Phase 1
Completed NCT01517581 - Brown Fat Activity and White Fat Accumulation N/A
Completed NCT00515554 - HD18 for Advanced Stages in Hodgkins Lymphoma Phase 3
Terminated NCT01326728 - Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation
Completed NCT00837200 - Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies Phase 2
Terminated NCT02603419 - Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS) Phase 1
Active, not recruiting NCT02099266 - Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment N/A
Completed NCT02057445 - 3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma Phase 1
Terminated NCT01300611 - TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation Phase 1
Completed NCT01014507 - Protection of Ovarian Function in Female Patients With Hodgkin Lymphoma Phase 2
Enrolling by invitation NCT00923442 - Biology Studies of Hematologic Cancers
Terminated NCT00973804 - Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders Phase 1
Completed NCT00739141 - Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. Phase 2
Recruiting NCT05134740 - (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL). Phase 1
Completed NCT01572662 - Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning Phase 2